Search
for
Sort by
Research 91–120 of 1000+
- Clinical positioning and future prospects of JAK inhibitors in alopecia areata
- Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation
- Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis
- Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways
- Irish dermatologists’ experience with JAK inhibitors in alopecia areata
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- When JAK inhibitors are off the table: durable remission of severe alopecia areata with dexamethasone oral mini-pulse and a focused review
- Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
- Treatment of alopecia areata with JAK inhibitors
- 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
- Jak inhibitors in the treatment of alopecia areata - a literature review
- JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
- Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Experience in treating multifocal alopecia areata in a child with Jak kinase inhibitors
- A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System
- Letter to the Editor: A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Healthcare System
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- Alopecia Areata: JAK Inhibitors—PRP and Exosomes
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege